Zacks Investment Research Lowers Catasys (NASDAQ:CATS) to Hold
According to Zacks, “Catasys, Inc., formerly known as Hythiam, Inc., provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Company’s program seeks to improve member health by delivering medical and psychosocial interventions in combination with long term care coaching, including their proprietary treatment program for alcoholism and stimulant dependence. Catasys, Inc. is based in Los Angeles. “
CATS has been the topic of several other reports. Dougherty & Co assumed coverage on Catasys in a research note on Tuesday, May 7th. They issued a “buy” rating on the stock. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Canaccord Genuity reduced their price objective on Cronos Group from C$17.00 to C$16.00 in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $19.00.
Catasys (NASDAQ:CATS) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The firm had revenue of $6.81 million for the quarter, compared to analyst estimates of $5.64 million. Equities analysts expect that Catasys will post -0.96 earnings per share for the current year.
In related news, major shareholder David E. Smith sold 50,815 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $15.78, for a total value of $801,860.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder David E. Smith sold 16,692 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $17.29, for a total value of $288,604.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 401,811 shares of company stock worth $6,465,985. Insiders own 60.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. WINTON GROUP Ltd purchased a new position in shares of Catasys in the 2nd quarter valued at $227,000. Kennedy Capital Management Inc. grew its stake in Catasys by 7.3% during the 1st quarter. Kennedy Capital Management Inc. now owns 301,087 shares of the company’s stock worth $3,682,000 after buying an additional 20,469 shares during the last quarter. CIBC Private Wealth Group LLC purchased a new position in Catasys during the 1st quarter worth $187,000. Janney Montgomery Scott LLC grew its stake in Catasys by 19.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 171,223 shares of the company’s stock worth $2,094,000 after buying an additional 27,467 shares during the last quarter. Finally, Westwood Management Corp IL grew its stake in Catasys by 37.5% during the 1st quarter. Westwood Management Corp IL now owns 55,000 shares of the company’s stock worth $673,000 after buying an additional 15,000 shares during the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.
Catasys Company Profile
Catasys, Inc provides big data predictive analytics, artificial intelligence and telehealth, combined with human intervention services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services.
Recommended Story: Insider Trading – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.